News | November 02, 2023
Zydus acquires UK based LiqMeds Group
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Clindamycin Phosphate Gel is used to treat acne
Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day had annual sales of US $330 million in the United States
Erythromycin tablets is used to prevent and treat infections in many different parts of the body
Zinc Sulfate Injection is indicated in adult and paediatric patients as a source of zinc for parenteral nutrition
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Subscribe To Our Newsletter & Stay Updated
